Cosmos Health Inc. (COSM)
Healthcare
- Fundamental
- 1
- Sentiment
- 1
- Technical
- 2
Do Nothing: fundamentalScore 1 and qualitativeScore 1 are both below the required floor of 3 (going-concern distress and ~20.5M-share dilutive conversion overhang); additionally avgDollarVolume20 ≈ $0.67M is below the $5M liquidity floor and the recent 3-session average ≈ $0.63M is below the $1.5M recent-liquidity floor.
Company overview
Cosmos Health Inc. functions as a vertically integrated pharmaceutical firm, providing its own line of branded and generic medicines, nutraceuticals, non-prescription drugs, healthcare and infant products, medical devices, and various other goods. These are distributed via its established channels and an e-commerce marketplace. The company actively seeks, obtains, develops, and commercializes solutions designed to improve patients' well-being and health outcomes. Supporting these operations, it maintains distribution centers in both Greece and the United Kingdom, alongside a dedicated warehousing facility. Its clientele includes wholesale pharmaceutical distributors and independent retail pharmacies. Cosmos Health Inc. was established in 2009 and has its headquarters in Chicago, Illinois.
Fundamental
very weakCOSM's fundamentals are too risky, with going-concern doubts and persistent losses.
Speculative, cash-burning micro-cap under an explicit going-concern warning: five straight years of negative operating cash flow, only ~$1.8M of unrestricted cash against $34.8M in current liabilities, ~$20M of debt, heavy reliance on dilutive convertible-note and ATM financing, a late-filed 10-Q, and an Altman Z-Score of -2.83 deep in the distress zone. Revenue is growing (+29.7% H1 2026) and the CEO keeps buying stock, but losses are widening, both discounted-cash-flow models return negative per-share values, and the low price multiples reflect distress rather than value — too risky to invest.
Sentiment
very weakSentiment is capped by going-concern disclosures despite some positive insider activity.
Dominant near-term driver is distress, not growth: the 2026-08-19 earnings print (announced) delivered record revenue but an EPS miss, alongside a same-week 10-Q (2026-08-18) reaffirming going-concern doubt while ~20.48M conversion shares hit the tape; sentiment delta is determinate but flat (~+0.44 → ~+0.50, PR-syndication-driven), retail velocity is indeterminate with promo-only chatter, and the severe red-flag cap applies (going-concern/auditor doubt plus distress-context dilutive financing).
Technical
weakCOSM is in a strong downtrend with oversold indicators and insufficient liquidity.
Score 2 (mostly weak-bearish, bounce-only): price 0.2066 trades below SMA20 (0.21), SMA50 (0.22) and SMA200 (0.37), below EMA9/21 and the daily VWAP (0.216); MACD line negative (-0.01) with ADX 30.7 — a strong down trend, not a bullish one; RSI 46.3 and Williams %R -60.4 are weak-neutral. Only mild positives: the 08-19 low of 0.1781 has held two sessions and the MACD histogram has flattened to ~0. No trend, momentum or volume confirmation for a bullish entry; score reflects bounce-only chart quality.
You’re looking at 2026-08-25 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.